Spartan Capital Securities, LLC Serves as Placement Agent in Lixte Biotechnology Holdings, Inc.'s $4.3 Million Registered Direct Offering

On December 22, 2025, Spartan Capital Securities, LLC announced its role as the exclusive placement agent in a $4.3 million registered direct offering for Lixte Biotechnology Holdings, Inc. (NASDAQ: LIXT), a clinical-stage pharmaceutical company focused on cancer treatment advancements. The transaction involved agreements with accredited investors for the purchase of Common Stock, pre-funded units, and investor warrants, complying with Nasdaq pricing regulations.

The offering included 1,051,342 Common Units and Pre-Funded Units, where each Common Unit consisted of one share of Common Stock and a warrant to purchase one additional share at an exercise price of $3.96. Each Pre-Funded Unit contained a Pre-Funded Warrant, priced at $0.00001, alongside a Common Warrant. The public offering price was set at $4.09 for each Common Unit and $4.08999 for Pre-Funded Units. The Common Warrants are immediately exercisable and will expire in sixty months.

This capital raise is expected to yield approximately $4.3 million in gross proceeds, with net proceeds intended to bolster Lixte's general corporate purposes and working capital. Spartan Capital's CEO, John Lowry, emphasized their commitment to supporting innovative life sciences firms with tailored financial solutions, recognizing Lixte's compelling clinical program in oncology.

The registered direct offering was executed under an existing effective shelf registration statement filed with the U.S. Securities and Exchange Commission (SEC) in May 2024. Legal counsel for Lixte was provided by Sichenzia Ross Ference Carmel LLP, while Kaufman and Canoles, P.C. represented Spartan Capital.

Overall, Spartan Capital Securities continues to facilitate growth in the life sciences sector, aligning investment opportunities with strategic objectives for companies like Lixte Biotechnology Holdings. For more information, visit their respective websites.

In light of Spartan Capital Securities, LLC's recent role as the exclusive placement agent for Lixte Biotechnology Holdings, Inc.'s $4.3 million registered direct offering, investors should consider key elements that may affect the market positioning of both entities and the potential investment merits of Lixte itself.

Lixte Biotechnology is operating within a critical sector—oncology. With its lead compound, LB 100, showing promise in clinical trials for severe conditions like ovarian clear cell carcinoma and metastatic colon cancer, investor interest could intensify as results from these trials are expected to shape the company's future. The recent capital raise is crucial for sustaining ongoing clinical programs and could enhance Lixte's operational flexibility, which is vital for a clinical-stage biotech firm.

The terms of the offering, with the public offering priced at $4.09 for Common Units including warrants, suggest a strategic valuation aimed at attracting accredited investors while staying compliant with Nasdaq regulations. Given that the exercise price for these warrants is set at $3.96, this presents a potential upside for early investors if the company's developments yield positive results, pushing the stock price beyond the warrant exercise price.

Analysts should monitor Lixte’s advancements in clinical trials closely and evaluate news flow for any significant announcements which may directly influence its stock performance. Furthermore, the backing from a reputable firm like Spartan Capital Securities, known for its focus on innovative life sciences, adds an additional layer of credibility to Lixte's growth narrative.

Investors might view this offering as a potential entry point into a high-risk but potentially high-reward landscape, contingent upon clinical success and effective execution of its corporate strategy. It’s advisable to review ongoing developments and market responses before making investment decisions.